Free tool
FAERS Monitor: Lidocaine Hydrochloride 0.8% and Dextrose 5% In Plastic Container
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018461 or its brand name (Lidocaine Hydrochloride 0.8% and Dextrose 5% In Plastic Container, Lidocaine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,041
Serious
4,863
69% of reports
Hospitalization
2,546
Death reported
583
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infusion site pain792
- drug ineffective575
- nausea517
- infusion site erythema494
- headache464
- dyspnoea449
- diarrhoea445
- off label use430
- fatigue390
- pain374
- infusion site swelling345
- dizziness325
- vomiting314
- hypotension243
- infusion site haemorrhage233
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 35 |
| 2005 | 18 |
| 2006 | 9 |
| 2007 | 9 |
| 2008 | 28 |
| 2009 | 51 |
| 2010 | 50 |
| 2011 | 64 |
| 2012 | 85 |
| 2013 | 90 |
| 2014 | 57 |
| 2015 | 166 |
| 2016 | 121 |
| 2017 | 139 |
| 2018 | 171 |
| 2019 | 168 |
| 2020 | 199 |
| 2021 | 324 |
| 2022 | 593 |
| 2023 | 990 |
| 2024 | 1,457 |
| 2025 | 1,368 |
| 2026 | 849 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,118 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion site haemorrhageSignal | 233 | 227.6 | 199.6 | 48,646 |
| infusion site painSignal | 792 | 195.5 | 182.7 | 143,774 |
| infusion site erythemaSignal | 494 | 185.9 | 170.2 | 85,374 |
| infusion site swellingSignal | 345 | 173.2 | 155.8 | 55,696 |
| hypotensionSignal | 243 | 3.6 | 3.2 | 462 |
| dyspnoeaSignal | 449 | 2.4 | 2.2 | 364 |
| headacheSignal | 464 | 2.2 | 2.0 | 316 |
| diarrhoeaSignal | 445 | 2.1 | 1.9 | 249 |
| vomiting | 314 | 2.0 | 1.8 | 158 |
| nausea | 517 | 2.0 | 1.8 | 248 |
| dizziness | 325 | 1.9 | 1.8 | 152 |
| pain | 374 | 1.8 | 1.6 | 141 |
| fatigue | 390 | 1.5 | 1.4 | 66 |
| off label use | 430 | 1.5 | 1.3 | 66 |
| drug ineffective | 575 | 1.3 | 1.2 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.